vs
Regional Management Corp.（RM）与Vericel Corp（VCEL）财务数据对比。点击上方公司名可切换其他公司
Regional Management Corp.的季度营收约是Vericel Corp的1.8倍（$167.3M vs $92.9M），Vericel Corp净利率更高（25.0% vs 6.8%，领先18.2%），Vericel Corp同比增速更快（23.3% vs 9.4%），过去两年Vericel Corp的营收复合增速更高（34.6% vs 8.2%）
千禧管理有限责任公司是一家提供多策略对冲基金服务的投资管理机构，也是全球规模最大的另类资产管理机构之一，截至2026年1月，其管理资产规模达834亿美元，业务覆盖美洲、欧洲与亚洲。自1989年成立以来，截至2022年，该机构累计净收益在全球对冲基金中排名第四。
Vericel Corp是一家美国上市生物制药企业，前身为1989年在密歇根州安娜堡成立的Aastrom Bio，2014年10月正式更为现名，专注于生物制药相关领域的研发与商业化运营。
RM vs VCEL — 直观对比
营收规模更大
RM
是对方的1.8倍
$92.9M
营收增速更快
VCEL
高出13.9%
9.4%
净利率更高
VCEL
高出18.2%
6.8%
两年增速更快
VCEL
近两年复合增速
8.2%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $167.3M | $92.9M |
| 净利润 | $11.4M | $23.2M |
| 毛利率 | — | 78.7% |
| 营业利润率 | — | 24.1% |
| 净利率 | 6.8% | 25.0% |
| 营收同比 | 9.4% | 23.3% |
| 净利润同比 | 62.7% | 17.3% |
| 每股收益（稀释后） | $1.18 | $0.46 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收RMVCEL
| Q1 26 | $167.3M | — | ||
| Q4 25 | $169.7M | $92.9M | ||
| Q3 25 | $165.5M | $67.5M | ||
| Q2 25 | $157.4M | $63.2M | ||
| Q1 25 | $153.0M | $52.6M | ||
| Q4 24 | $154.8M | $75.4M | ||
| Q3 24 | $146.3M | $57.9M | ||
| Q2 24 | $143.0M | $52.7M |
净利润RMVCEL
| Q1 26 | $11.4M | — | ||
| Q4 25 | $12.9M | $23.2M | ||
| Q3 25 | $14.4M | $5.1M | ||
| Q2 25 | $10.1M | $-553.0K | ||
| Q1 25 | $7.0M | $-11.2M | ||
| Q4 24 | $9.9M | $19.8M | ||
| Q3 24 | $7.7M | $-901.0K | ||
| Q2 24 | $8.4M | $-4.7M |
毛利率RMVCEL
| Q1 26 | — | — | ||
| Q4 25 | — | 78.7% | ||
| Q3 25 | — | 73.5% | ||
| Q2 25 | — | 73.7% | ||
| Q1 25 | — | 69.0% | ||
| Q4 24 | — | 77.6% | ||
| Q3 24 | — | 71.9% | ||
| Q2 24 | — | 69.5% |
营业利润率RMVCEL
| Q1 26 | — | — | ||
| Q4 25 | 9.5% | 24.1% | ||
| Q3 25 | 11.5% | 5.1% | ||
| Q2 25 | 8.6% | -3.2% | ||
| Q1 25 | 6.0% | -24.3% | ||
| Q4 24 | 8.2% | 24.5% | ||
| Q3 24 | 6.9% | -4.3% | ||
| Q2 24 | 7.8% | -11.5% |
净利率RMVCEL
| Q1 26 | 6.8% | — | ||
| Q4 25 | 7.6% | 25.0% | ||
| Q3 25 | 8.7% | 7.5% | ||
| Q2 25 | 6.4% | -0.9% | ||
| Q1 25 | 4.6% | -21.4% | ||
| Q4 24 | 6.4% | 26.3% | ||
| Q3 24 | 5.2% | -1.6% | ||
| Q2 24 | 5.9% | -8.9% |
每股收益（稀释后）RMVCEL
| Q1 26 | $1.18 | — | ||
| Q4 25 | $1.30 | $0.46 | ||
| Q3 25 | $1.42 | $0.10 | ||
| Q2 25 | $1.03 | $-0.01 | ||
| Q1 25 | $0.70 | $-0.23 | ||
| Q4 24 | $0.96 | $0.40 | ||
| Q3 24 | $0.76 | $-0.02 | ||
| Q2 24 | $0.86 | $-0.10 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $137.5M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $375.8M | $354.6M |
| 总资产 | $2.1B | $488.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资RMVCEL
| Q1 26 | — | — | ||
| Q4 25 | — | $137.5M | ||
| Q3 25 | — | $135.4M | ||
| Q2 25 | — | $116.9M | ||
| Q1 25 | — | $112.9M | ||
| Q4 24 | — | $116.2M | ||
| Q3 24 | — | $101.7M | ||
| Q2 24 | — | $102.5M |
总债务RMVCEL
| Q1 26 | — | — | ||
| Q4 25 | $1.6B | — | ||
| Q3 25 | $1.6B | — | ||
| Q2 25 | $1.5B | — | ||
| Q1 25 | $1.5B | — | ||
| Q4 24 | $1.5B | — | ||
| Q3 24 | $1.4B | — | ||
| Q2 24 | $1.4B | — |
股东权益RMVCEL
| Q1 26 | $375.8M | — | ||
| Q4 25 | $373.1M | $354.6M | ||
| Q3 25 | $371.9M | $321.9M | ||
| Q2 25 | $363.0M | $306.8M | ||
| Q1 25 | $357.9M | $295.5M | ||
| Q4 24 | $357.1M | $292.0M | ||
| Q3 24 | $352.9M | $257.5M | ||
| Q2 24 | $344.9M | $243.0M |
总资产RMVCEL
| Q1 26 | $2.1B | — | ||
| Q4 25 | $2.1B | $488.0M | ||
| Q3 25 | $2.0B | $453.3M | ||
| Q2 25 | $2.0B | $435.6M | ||
| Q1 25 | $1.9B | $424.6M | ||
| Q4 24 | $1.9B | $432.7M | ||
| Q3 24 | $1.8B | $390.4M | ||
| Q2 24 | $1.8B | $376.8M |
负债/权益比RMVCEL
| Q1 26 | — | — | ||
| Q4 25 | 4.40× | — | ||
| Q3 25 | 4.23× | — | ||
| Q2 25 | 4.14× | — | ||
| Q1 25 | 4.11× | — | ||
| Q4 24 | 4.12× | — | ||
| Q3 24 | 3.94× | — | ||
| Q2 24 | 3.98× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $15.0M |
| 自由现金流经营现金流 - 资本支出 | — | $12.8M |
| 自由现金流率自由现金流/营收 | — | 13.8% |
| 资本支出强度资本支出/营收 | — | 2.4% |
| 现金转化率经营现金流/净利润 | — | 0.65× |
| 过去12个月自由现金流最近4个季度 | — | $24.7M |
8季度趋势，按日历期对齐
经营现金流RMVCEL
| Q1 26 | — | — | ||
| Q4 25 | $309.1M | $15.0M | ||
| Q3 25 | $86.7M | $22.1M | ||
| Q2 25 | $78.7M | $8.2M | ||
| Q1 25 | $63.7M | $6.6M | ||
| Q4 24 | $268.9M | $22.2M | ||
| Q3 24 | $75.1M | $10.2M | ||
| Q2 24 | $71.5M | $18.5M |
自由现金流RMVCEL
| Q1 26 | — | — | ||
| Q4 25 | $304.3M | $12.8M | ||
| Q3 25 | $85.7M | $19.5M | ||
| Q2 25 | $77.6M | $81.0K | ||
| Q1 25 | $62.4M | $-7.6M | ||
| Q4 24 | $263.9M | $8.5M | ||
| Q3 24 | $73.8M | $-9.2M | ||
| Q2 24 | $70.3M | $1.8M |
自由现金流率RMVCEL
| Q1 26 | — | — | ||
| Q4 25 | 179.3% | 13.8% | ||
| Q3 25 | 51.8% | 28.8% | ||
| Q2 25 | 49.3% | 0.1% | ||
| Q1 25 | 40.8% | -14.5% | ||
| Q4 24 | 170.4% | 11.2% | ||
| Q3 24 | 50.4% | -15.9% | ||
| Q2 24 | 49.1% | 3.4% |
资本支出强度RMVCEL
| Q1 26 | — | — | ||
| Q4 25 | 2.8% | 2.4% | ||
| Q3 25 | 0.6% | 3.9% | ||
| Q2 25 | 0.6% | 12.9% | ||
| Q1 25 | 0.8% | 27.0% | ||
| Q4 24 | 3.3% | 18.3% | ||
| Q3 24 | 0.9% | 33.5% | ||
| Q2 24 | 0.8% | 31.8% |
现金转化率RMVCEL
| Q1 26 | — | — | ||
| Q4 25 | 23.94× | 0.65× | ||
| Q3 25 | 6.04× | 4.35× | ||
| Q2 25 | 7.76× | — | ||
| Q1 25 | 9.09× | — | ||
| Q4 24 | 27.13× | 1.12× | ||
| Q3 24 | 9.80× | — | ||
| Q2 24 | 8.47× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
RM
暂无分部数据
VCEL
| MACI Implants And Kits | $84.1M | 90% |
| Other | $8.8M | 10% |
